2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1084
    β-Pompilidotoxin 216064-36-7
    β-Pompilidotoxin (β-PMTX), a wasp venom, can slow sodium channel inactivation and increases steady-state sodium current in cells.
    β-Pompilidotoxin
  • HY-P1183
    Locustatachykinin I 126985-97-5 99.90%
    Locustatachykinin I is a insect tachykinin-related peptide isolated from Locusta migratoria. Locustatachykinin I exhibits sequence homologies with the vertebrate tachykinins. In Lacanobia, Locustatachykinin I is also a substrate for a deamidase.
    Locustatachykinin I
  • HY-P1198
    Hemokinin 1, human 491851-53-7 98.11%
    Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia.
    Hemokinin 1, human
  • HY-P1297
    CRF(6-33)(human) 120066-38-8 99.61%
    CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.
    CRF(6-33)(human)
  • HY-P1303
    CART(62-76)(human,rat) 210978-19-1
    CART(62-76)(human,rat) is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain.
    CART(62-76)(human,rat)
  • HY-P1448
    Ac-Leu-Arg-AMC 929621-79-4 98.17%
    Ac-Leu-Arg-AMC is a fluorogenic peptide substrate.
    Ac-Leu-Arg-AMC
  • HY-P1468
    β-Amyloid (1-28) 109770-29-8
    β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-28)
  • HY-P1517
    β-Amyloid (31-35) 149385-65-9 99.10%
    β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.
    β-Amyloid (31-35)
  • HY-P1530
    Prolactin Releasing Peptide (12-31), human 235433-36-0 98.85%
    Prolactin Releasing Peptide (12-31), human is a fragment of the prolactin releasing peptide (PrRP). Prolactin Releasing Peptide (1-31), human is a high affinity GPR10 ligand that cause the release of the prolactin.
    Prolactin Releasing Peptide (12-31), human
  • HY-P1596
    Gluten Exorphin C 142479-62-7 99.86%
    Gluten exorphin C is an opioid peptide derived from wheat gluten. Its IC50 values are 40 μM and 13.5 μM for μ opioid and δ opioid activities in the GPI and MVD assays, respectively.
    Gluten Exorphin C
  • HY-P1738
    [Sar9] Substance P 77128-75-7 98.14%
    [Sar9] Substance P is a potent and selective neurokinin (NK)-1 receptor agonist.
    [Sar9] Substance P
  • HY-P1805
    Calmodulin Binding Peptide 1 104041-80-7 98.68%
    Calmodulin Binding Peptide 1 is a high-affinity (pM) CaM-binding peptide derived from smooth muscle myosin light chain kinase (MLCK peptide). The interface of the complex formed by Calmodulin Binding Peptide 1 and Ca2+-CaM can be specifically bound by small-molecule inhibitors, serving as a key target for selective regulation of smooth muscle contraction and development of anti-CaM drugs.
    Calmodulin Binding Peptide 1
  • HY-P1962
    β-Secretase inhibitor 350228-37-4 98.06%
    β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC50: 25 nM for β-secretase).
    β-Secretase inhibitor
  • HY-P2155
    BigLEN(rat) 369377-66-2 99.73%
    BigLEN(rat) is a potent GPR171 agonist with an EC50 of 1.6 nM.
    BigLEN(rat)
  • HY-P2283
    β-Amyloid (1-37) (human) 186359-67-1 98.81%
    β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value.
    β-Amyloid (1-37) (human)
  • HY-P2285
    AC 253 151804-79-4 98.54%
    AC 253, an amylin antagonist, inhibits 125I-adrenomedullin binding, with an IC50 of 25 nM.
    AC 253
  • HY-P2750
    Cathepsin D 9025-26-7
    Cathepsin D (CTSD) is a lysosomal aspartic protease encoded by the CTSD gene. Cathepsin D regulates lysosomal protease activity. Loss of Cathepsin D leads to lysosomal dysfunction and the accumulation of various cellular proteins associated with neurodegenerative diseases. Cathepsin D is involved in breast cancer metastasis. Cathepsin D can be used in research on diseases such as breast cancer and stroke.
    Cathepsin D
  • HY-P2912
    Glutamate dehydrogenase (NADP) 9029-11-2
    Glutamate dehydrogenase (NADP) is the catalytic enzyme for glutamate production. Dysfunction of Glutamate dehydrogenase (NADP) may induce various neurodegenerative diseases, such as Parkinson's disease, epilepsy, Alzheimer's disease, schizophrenia, and frontotemporal dementia. Glutamate dehydrogenase (NADP) can be used in research on neurological diseases such as Parkinson's disease, epilepsy, and Alzheimer's disease.
    Glutamate dehydrogenase (NADP)
  • HY-P3618
    Cortistatin-29 (reduced) 98.12%
    Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects.
    Cortistatin-29 (reduced)
  • HY-P3678
    Neuropeptide Y (18-36) (porcine) 114495-97-5 98.76%
    Neuropeptide Y (18-36) (porcine) is a competitive neuropeptide Y (NPY) cardiac receptor antagonist. Neuropeptide Y (18-36) (porcine) inhibits the binding of I-NPY to cardiac ventricular membranes in a concentration-dependent manner with an IC50 value of 158 nM and an Ki value of 140 nM. Neuropeptide Y (18-36) (porcine) can be used for the research of congestive heart failure.
    Neuropeptide Y (18-36) (porcine)
Cat. No. Product Name / Synonyms Application Reactivity